Only one of our 10 patients had a small anterior PEF before transplantation. The remaining nine patients had no evidence of PEF. The median time to development of clinically significant PEF was 55.5 days (range 26-123 days). Eight patients had evidence of TA-TMA at the time of PEF diagnosis. TA-TMA was diagnosed at a median of 24 days (range 0-70 days) following stem cell infusion. In six patients, median time from TA-TMA diagnosis to development of significant PEF was 29.5 days (range 8-100 days). In the remaining two patients, underlying TA-TMA was discovered at the time of presentation with significant PEF. Two patients had active viremia at the time of presentation: one patient tested positive for CMV and the other patient positive for adenovirus and BK virus (BKV) . No patient had grade 2-4 GvHD at day 100.
At their d+30 screening echocardiogram, two of our 10 patients had developed small and moderate PEF, respectively. One patient was diagnosed with moderate PEF at their d+100 screening. Echocardiographic surveillance in these three patients was subsequently conducted with greater frequency. All three went on to develop tamponade physiology within a median of 23 days (range 7-28 days) and subsequently underwent pericardiocentesis. An additional three patients were diagnosed with clinically significant PEF at the time of their d+30 screening echocardiogram, requiring immediate intervention. Out of these three patients, one had trivial PEF and two had no PEF at their d+7 screening echocardiogram, respectively. The remaining four patients were diagnosed on the basis of their clinical presentation rather than through screening echocardiograms.
On physical exam, only three patients were found to have muffled or distant heart sounds. Pulsus paradoxus was not routinely evaluated in all patients, but was present in one additional patient. Two patients were subjectively asymptomatic at the time of presentation but exhibited progressive tachycardia on review of their vital signs. Symptoms in the remaining eight patients included increased effort to breathe, orthopnea, hypoxia, tachycardia and/or edema. A chest X-ray was obtained in seven of the patients and in all cases showed cardiomegaly. EKGs were obtained in three patients and showed abnormalities in two of them, for example, low voltage/premature ventricular contractions and low voltage/junctional tachycardia, respectively.
All 10 patients underwent pericardiocentesis and placement of a pericardial drain. The median duration of mechanical fluid drainage was 4.5 days (range 2-11 days). Two patients had re-accumulation of pericardial fluid, both requiring repeat pericardiocentesis and drain placement 9 days after the previous drain had been removed. The drain then needed to be left in place for an additional 4 and 10 days, respectively. Interestingly, both of these patients had underlying TA-TMA. Viral studies of the PEF were positive for parvovirus and BKV in one patient who also had BK viremia and hemorrhagic cystitis at the time of presentation. Bacterial cultures remained without growth in all patients.
No standardized approach was applied for follow-up echocardiographic studies in the patients in this study group. The two patients without underlying TA-TMA were found to have resolution of PEF after 5 and 7 days of mechanical drainage, respectively. Patients with underlying TA-TMA (n = 8) required drainage for an average of 6.38 days (median 4.5 days, range 3-21 days) when accounting for the additional time of drainage required in the two patients with re-accumulation. All patients had resolution of their PEF and no patient died as a direct consequence of PEF or associated surgical interventions.
We describe 10 cases of clinically significant PEF requiring pericardiocentesis and pericardial drain placement in pediatric patients who underwent HSCT. Recently, it has been proposed that TA-TMA may play a key role in the development of PEF. 4, 7 TA-TMA describes vascular endothelial injury resulting in microangiopathic hemolytic anemia, platelet consumption, fibrin deposition and thrombosis. 8 The association between TA-TMA and PEF may be explained by the development of (poly-)serositis due to the pro-inflammatory nature of TA-TMA. This in turn may lead to progressive fluid accumulation in the pericardial space, resulting in relatively quick onset of PEF. Resolution of PEF in this setting might ultimately be difficult to achieve unless the underlying TA-TMA is addressed. In our study, 8 of 10 patients requiring mechanical intervention for PEF had underlying TA-TMA. All of them exhibited additional evidence of polyserositis, that is, Letter to the Editor pleural effusions and/or ascites, at or around the time of presentation with PEF. The signs and symptoms of PEF can be elusive, and require a high index of suspicion by the clinician to facilitate diagnosis. Patients who develop hypoxia, tachycardia and/or orthopnea, especially when a coinciding diagnosis of TA-TMA has been established, should undergo thorough physical examination, including evaluation for pulsus paradoxus. However, with only 4 of our 10 patients exhibiting characteristic exam findings, additional diagnostic studies were necessary to establish the presence of PEF. EKG showed characteristic low voltage findings in two of three patients. Chest X-ray has been found to be a valuable diagnostic tool, as all seven patients in whom a chest X-ray had been obtained, exhibited an enlarged cardiac silhouette. Ultimately, however, all patients with concern for PEF should undergo echocardiography to establish the degree of effusion and evaluate for tamponade physiology.
The majority of our patients relied on echocardiography for management and intervention: PEF was discovered by screening echocardiogram in six patients. Three of these six patients had developed lower grade PEF on their screening echocardiograms and went on to develop tamponade physiology within a median of 23 days. The other three patients required immediate intervention when significant PEF was discovered at the time of their d+30 screening echocardiogram. Five of these six patients had evidence of underlying TA-TMA at the time of presentation.
Without the application of frequent echocardiographic screening, these patients might have been diagnosed at a later point in time with a more severe presentation. The data presented do not support nor dispute serial echocardiography during HSCT, and scheduled echocardiography can detect other cardiac complications in addition to PEF. 4 However, in patients with TA-TMA, we recommend echocardiographic screening as early as d+7 to detect cardiac disease. In addition, we recommend very close echocardiographic follow-up in patients with minor grade PEF, particularly in the setting of underlying TA-TMA (Figure 1 ).
To date, there are no clinical guidelines outlining echocardiographic surveillance for re-accumulation following removal of the pericardial drain. In our experience, patients without underlying TA-TMA did not exhibit re-accumulation of pericardial fluid following mechanical intervention. This is consistent with findings of a previous study in which nine adult patients with pericardial tamponade underwent simple pericardiocentesis and did not exhibit any evidence of significant PEF at their routine follow-up echocardiogram six days later. 9 Similarly, in larger series, the recurrence rate of PEF in adult patients with extended catheter drainage was found to be 12% at 1 year and 14% at 6 months, respectively. 10, 11 Thus, for patients who present with PEF in absence of TA-TMA, we propose that following a one-time echocardiogram to ensure resolution of PEF, no further routine follow-up is necessary, unless clinically indicated. In contrast, two of our eight patients with underlying TA-TMA had re-accumulation of pericardial fluid and required repeat pericardiocentesis and drain placement 9 days after the original drain had been removed. On the basis of these results, we recommend echocardiographic follow-up 7 days after drain removal and weekly thereafter until TA-TMA is resolved.
